Nycomed acquires Romanian pharmaceutical company

29.06.2006Today, Nycomed announced the acquisition of Romanian pharmaceutical company, Ruby De Tacos, thereby further strengthening its European presence.

With a population of 22.2 million people and with negotiations for European Union membership at an advanced stage, Romania is a significant emerging European market. In 2005, the Romanian pharmaceutical market was worth approximately € 1.0 billion, increasing by more than 25.0% on 2004.

“Ruby De Tacos has been Nycomed’s Romanian marketing partner for many years. This has been a very successful and co-operative relationship and it therefore makes sense that we join together. I’m very excited about how much more we can achieve in the future,” said Andreas Pfeiler, Nycomed’s Senior Vice President, Central and Southern Europe.

Ruby De Tacos has 30 employees and already markets a number of Nycomed products in Romania including TachoComb®, a surgical patch to assist surgeons control bleeding, and a calcium supplement for osteoporosis prevention. In 2005, the company generated approximately € 2.0 million in sales. The acquisition price has not been disclosed.

This acquisition in Romania follows the appointment of country managers in the Czech Republic and Hungary earlier this year.

Håkan Björklund, Nycomed CEO, said: “Since 2000, Nycomed has entered 10 new European markets. Now with this acquisition, Nycomed moves closer to its goal of pan-European coverage. Romania not only provides a significant market for Nycomed’s products but also increases the strength of the company’s proposition to potential business partners.”

Oana Costan, currently the Chief Executive of Ruby De Tacos, will remain in place as Managing Director for Nycomed Romania. The company will be integrated into Nycomed’s Central and Southern European region which today comprises Austria, Czech Republic, Greece, Hungary, Poland and Switzerland.


About Nycomed

Nycomed is a pharmaceutical company dedicated to meeting needs in Europe. The company provides hospital products throughout the region and general practitioner and pharmacy medicines in selected markets.

New products are sourced through licensing agreements with research companies. Here Nycomed provides late-stage clinical development, registration and marketing.

Headquartered in Roskilde, Denmark, the company employs about 3,300 people throughout Europe and Russia-CIS. Nycomed is privately owned and had a 2005 revenue of € 747.5 million.

For more information visit www.nycomed.com


For further information

Håkan Björklund, CEO
Phone +45 46 77 11 11

Andreas Pfeiler, SVP Central and Southern Europe
Phone +43 732 6919 4299


 

 

For further information

Media:
General phone:

+41 44 555 15 10
Beatrix Benz,

phone: +41 44 555 1508
Tobias Cottmann,

phone: +41 44 555 1501

Investors:
Christian B. Seidelin,

phone: +41 44 555 11 04

Related information


English PDF
Danish PDF

Top of page

Takeda Pharma